New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 26, 2014
10:00 EDTWCIC, INCY, TRVN, COV, ITCI, GOLD, KLIC, EPE, NUTR, IVAC, APL, RTEC, LJPC, HELIOn The Fly: Analyst Initiation Summary
Atlas Pipeline Partners (APL) initiated with a Hold at Deutsche Bank... CHC Group (HELI) initiated with a Buy at UBS... EP Energy (EPE) initiated with an Overweight at JPMorgan... Intevac (IVAC) initiated with a Neutral at B. Riley... Kulicke & Soffa (KLIC) initiated with a Buy at B. Riley... La Jolla Pharmaceutical (LJPC) initiated with an Outperform at Wedbush... Nutraceutical (NUTR) initiated with an Outperform at Imperial Capital... Randgold Resources (GOLD) initiated with a Buy at UBS... Rudolph Technologies (RTEC) initiated with a Buy at B. Riley... Trevena (TRVN) initiated with an Outperform at JMP Securities... WCI Communities (WCIC) reinstated with an Outperform at Credit Suisse... Covidien (COV) initiated with a Buy at CRT Capital... Incyte (INCY) coverage assumed with a Buy at BofA/Merrill... Intra-Cellular (ITCI) initiated with an Outperform at Cowen.
News For APL;EPE;HELI;IVAC;KLIC;LJPC;NUTR;GOLD;RTEC;TRVN;WCIC;COV;INCY;ITCI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
December 15, 2014
16:34 EDTTRVNCamber Capital reports 7.63% passive stake in Trevena
14:25 EDTTRVNNEA lowers stake in Trevena to 12.8% from 14.8%
Subscribe for More Information
11:09 EDTEPEEP Energy management to meet with Jefferies
Subscribe for More Information
December 12, 2014
16:19 EDTTRVNRA Capital reports 7.9% passive stake in Trevena
Subscribe for More Information
08:01 EDTINCYPiper predicts two large-cap biotechs could be acquired in 2015
Subscribe for More Information
December 10, 2014
07:49 EDTRTEC, IVACGuerrant Associates to hold a summit
Subscribe for More Information
December 9, 2014
16:06 EDTHELICHC Group reports Q3 EPS (31c), consensus (38c)
Subscribe for More Information
16:02 EDTLJPCLa Jolla, George Washington University announce worldwide license agreement
Subscribe for More Information
07:11 EDTINCYEli Lilly and Incyte announce Phase 3 RA-BEACON study met primary endpoint
Subscribe for More Information
December 8, 2014
13:07 EDTINCYNovartis announces data from Jakavi trial
Novartis (NVS) announced data from the largest clinical trial of myelofibrosis patients treated with Jakavi, supporting the safety profile and efficacy benefit as measured in primary and secondary endpoints respectively. In an analysis of 1,144 patients treated with Jakavi to date in this ongoing expanded access study, 69% of patients achieved >50% reduction in spleen size from baseline and patients also experienced a clinically meaningful improvement in myelofibrosis symptom score, important treatment goals for patients with myelofibrosis. Findings from the study were presented at the 56th Annual Meeting of the American Society of Hematology in San Francisco, California. Novartis research and development efforts, in collaboration with Incyte Corporation (INCY), include early-phase and post-marketing studies in myelofibrosis and other myeloproliferative neoplasms. More than 50 abstracts on ruxolitinib are being presented at ASH, including three oral presentations exploring combinations of ruxolitinib with various investigational compounds, evaluating the possibility of simultaneously targeting multiple cancer pathways that may be involved in the pathogenesis of myelofibrosis. The JUMP study is a Phase IIIb, expanded-access trial for countries with no access to Jakavi outside of a clinical trial. The open-label, multicenter study analyzed 1,144 enrolled myelofibrosis patients who received daily starting doses of either 5 mg, 15 mg or 20 mg of Jakavi twice daily based on platelet counts at baseline. The primary endpoint is assessment of safety and tolerability of Jakavi. Overall, the safety and efficacy profile of Jakavi was consistent with previous studies.
December 5, 2014
16:40 EDTINCYDiplomat Pharmacy: FDA approves expanded indication of Jakafi
Subscribe for More Information
09:49 EDTINCYIncyte polycythemia vera approval another upside driver, says UBS
Subscribe for More Information
09:17 EDTTRVNOn The Fly: Pre-market Movers
Subscribe for More Information
07:16 EDTINCYFDA PDUFA Date for Incyte's Jakafi (Ruxolitinib) is December 5, 2014
Subscribe for More Information
December 4, 2014
19:03 EDTTRVNTrevena 11.25M share Secondary priced at $4.00
Subscribe for More Information
15:04 EDTTRVNExistingTrevena investors want to buy $6.2M in shares as part of offering
Subscribe for More Information
11:23 EDTCOVAppeals court reverses patent ruling in favor of J&J unit over Covidien
Ethicon Endo-Surgery, a Johnson & Johnson (JNJ) company, appealed a district court judgment regarding certain asserted patent claims of Tyco Healthcare. The appeals court affirmed-in-part, reversed-in-part, and vacated-in-part the prior judgment, because the lower courtís 102(g) findings were correct, but its 103 determination was improper, "including its decision to exclude the 102(g) prior art from the obviousness analysis," the court stated. In 2007, Tyco Healthcare changed its name to Covidien (COV). Reference Link
10:49 EDTINCYFDA approves Jakafi to treat polycythemia vera
Subscribe for More Information
09:20 EDTHELICHC Group announces multimillion-pound project in Aberdeen
CHC Helicopter announced a multimillion-pound investment to transform CHCís facilities and further raise its capabilities in Dyce by significantly expanding hangar capacity, creating a larger and more streamlined passenger terminal, and providing for a new operations center. The development will be delivered in two phases. The first phase will double the size of the existing hangar. That work is planned to begin during the first half of calendar 2015. In the second phase, expected to start the following year, CHC will redevelop its passenger terminal, improving the experience for offshore workers. The transformed two-story terminal will include a new passenger lounge as well as dedicated space for CHCís major oil-and-gas customers.
08:24 EDTCOVChinese Ministry of Commerce clears Medtronic acquisition of Covidien
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use